While CBD is exploding across all markets, Cannabigerol or CBG could be just as important. It is often described as the “Mother of all cannabinoids” because it is the chemical source of all other plant-based cannabinoids. Like CBD, CBG delivers no overt psychoactivity, making it safe for children, seniors, and those in sensitive job positions.
In 2018 The National Center for Complementary and Integrative Health (NCCIH) announced an intent to research minor cannabinoids including CBG that could help manage pain. The NCCIH wrote that minor cannabinoids are defined as all and any cannabinoids from the cannabis herb other than Δ9-tetrahydrocannabinol (Δ9-THC). Cannabinoids and terpenes of particular interest include: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene, ß-caryophyllene, Limonene, a-terpineol, Linalool, a-phellandrene, a-pinene, ß-pinene, Y-terpinene, and a-humulene.
“This initiative intends to support highly innovative basic and/or mechanistic studies in appropriate model organisms and/or human subjects aiming to identify, describe and predict if minor cannabinoids and/or terpenes can help treat pain. The mechanisms and processes underlying potential contribution of minor cannabinoids and terpenes to pain relief and functional restoration in patients with different pain conditions may be very broad.”
Consumers don’t hear very much about CBG because it is difficult to produce and expensive to boot. The cannabis plants make lots of THC and CBD, but CBG is usually only present in small percentages. That is why it is called a “minor”cannabinoid. CBG can be five to six times more expensive than CBD.
The report noted that Cannabigerol or CBG, is one of a family of more than 100 molecules called cannabinoids that are produced by cannabis. “CBG is unique among its peers due to the pivotal role that it plays in the synthesis of other cannabinoids and the overall chemical composition of the plant.” According to a 2018 research study, CBG binds with both CB1 and CB2 receptors. This gives CBG greater potential efficacy than cannabinoids that bind with only a single type of receptor, such as CB2. Reported the study’s authors, “The results indicate that CBG is indeed effective as a regulator of endocannabinoid signaling.”
The paper wrote, “You’ve probably heard of popular chemotypes like Sativa and Indica, or the lesser-known Ruderalis, but did you know scientists have discovered a possible 4th chemotype? Research goes back as far as 1987, but more recently, studies in 2002 and 2005 have documented a fourth chemotype that features extremely large volumes of CBG and very low levels of THC.”
The research found that CBG-dominant chemotypes consistently offer significantly larger volumes of the “companion molecule” CBD. Those molecules join forces to provide additional effectiveness for systemic inflammation, anxiety, and pain. Some studies suggest that CBGV also boosts CBD metabolism within the body, making CBD more potent when paired with this cannabinoid.
Numerous Studies Cited In White Paper
The white paper lists an exhaustive compilation of CBG studies including a 2018 study entitled “Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors” that was published in the journal Frontiers in Pharmacology investigated the binding affinity of CBG with the CB1 and CB2 receptors of the ECS. The study reported, “The results indicate that CBG is indeed effective as [a] regulator of endocannabinoid signaling.”
A 2017 research study involving mice entitled “Beneficial Effect of the Non-psychotropic Plant Cannabinoid Cannabigerol on Experimental Inflammatory Bowel Disease” that was published in the journal Biochemical Pharmacology explored how CBG might help those suffering from inflammatory bowel disease (IBD). “We investigated the effect of CBG, a non-psychotropic cannabis-derived cannabinoid, in a murine model of colitis,” reported the study.
Stated the researchers, “CBG attenuated murine colitis, reduced nitric oxide production in macrophages (effect being modulated by the CB2 receptor),” concluding that “CBG could be considered for clinical experimentation in IBD patients.”
A 2016 research study entitled “Cannabigerol is a Novel, Well-tolerated Appetite Stimulant” that was published in the journal Psychopharmacology investigated the ability of CBG to stimulate appetite (hyperphagia) and was the first to prove that this molecule increases appetite. The study also identified the safety profile of CBG, reporting that it conveyed “no adverse effects on any parameter in the neuromotor tolerability test battery.